• Study of TYRA-300-B01 tablets in patients with low grade, intermediate risk non-muscle invasive bladder cancer who have FGFR3 gene changes

    Recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Italy Spain
  • Study of MTX-463 compared to placebo to assess its safety and effectiveness in adults with idiopathic pulmonary fibrosis

    Recruiting

    2 1 1
    Investigated Diseases:
    Belgium Croatia France Ireland The Netherlands Spain
  • Safety and feasibility study of fecal microbiota transplant in stage II-III non-small cell lung cancer patients treated with durvalumab, carboplatin, paclitaxel and rifaximin

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Spain
  • Study of dapagliflozin to prevent heart complications during lymphoma treatment in patients receiving first-line therapy

    Recruiting

    2 1 1
    Investigated Drugs:
    Denmark
  • Evaluating intravenous lidocaine with intrathecal morphine for pain control in patients undergoing major abdominal surgery through laparotomy

    Recruiting

    3 1 1
    France
  • Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

    Recruiting

    3 1 1
    Investigated Drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +17
  • Study comparing ALG-000184 with tenofovir disoproxil in untreated adults with chronic hepatitis B virus infection

    Recruiting

    2 1 1
    Investigated Diseases:
    Bulgaria France Italy Romania Spain
  • Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Austria Czechia Denmark France Germany Greece +3
  • Study of drug combination therapy for patients with lymph node-positive esophageal and esophagogastric junction cancer using carboplatin, paclitaxel, fluorouracil, folinic acid, docetaxel and oxaliplatin

    Recruiting

    2 1 1 1
    The Netherlands

powered by